オンコロジーバイオマーカーの世界市場レポート 2025年

オンコロジーバイオマーカーの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR14.2％で296億4,000万米ドルに成長します。予測期間の成長は、次世代シーケンシング（ngs）の統合、バイオマーカーインフォマティクスの拡大、予測薬理ゲノミクスへの注力、エクソソームベースのバイオマーカーの急速な開発、空間トランスクリプトミクスの採用に起因すると考えられます。予測期間における主な動向には、標準化と品質保証、機能性バイオマーカーへのシフト、臨床試験におけるバイオマーカーの役割、免疫療法における応用拡大、治療反応のリアルタイムモニタリングなどがあります。

がんの罹患率の増加は、今後数年間におけるがんバイオマーカー市場の成長を促進すると予想されます。がんは、特定の細胞の制御不能な増殖によって特徴付けられ、その後全身に広がる可能性があります。腫瘍学バイオマーカーは、個人の体内の遺伝子、タンパク質、その他の物質を分析することで、がんの種類に関する貴重な洞察を提供します。例えば、2024年1月、米国政府機関である国立医学図書館は、2024年に米国で新たに発生するがん患者数は2,001,140人、がんに関連する死亡者数は611,720人になると予測しています。また、30歳から44歳の子宮頸がん、55歳以下の大腸がんの罹患率は、若年成人の間で毎年1％から2％ずつ上昇しています。このように、がん罹患率の上昇は、がんバイオマーカー市場に大きな影響を与えるものと思われます。

オンコロジーバイオマーカーの成長に寄与する重要な要因は、個別化医療の採用が増加していることです。個別化医療とは、患者一人ひとりの特性に合わせた治療を行う革新的なヘルスケア手法です。オンコロジーバイオマーカーの文脈では、個別化医療は特定のバイオマーカーを利用し、個人のがんに特有の遺伝的または分子的特徴を特定します。一例として、2022年に米国食品医薬品局（FDA）の医薬品評価研究センター（CDER）は37の新規分子生物学的製剤（NME）を承認したが、そのうち約34％（12製剤）は個別化医療連合（PMC）によって個別化医療に分類されました。したがって、個別化医療の採用拡大が腫瘍バイオマーカー市場拡大の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界オンコロジーバイオマーカーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のオンコロジーバイオマーカー市場：成長率分析
• 世界のオンコロジーバイオマーカー市場の実績：規模と成長, 2019-2024
• 世界のオンコロジーバイオマーカー市場の予測：規模と成長, 2024-2029, 2034F
• 世界オンコロジーバイオマーカー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のオンコロジーバイオマーカー市場バイオマーカーの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タンパク質バイオマーカー
• 遺伝子バイオマーカー
• その他のがんバイオマーカー
• 世界のオンコロジーバイオマーカー市場プロファイリングテクノロジーズ、実績と予測, 2019-2024, 2024-2029F, 2034F
• オミックス技術
• イメージング技術
• 免疫測定
• バイオインフォマティクス
• その他のプロファイリング技術
• 世界のオンコロジーバイオマーカー市場がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん
• 肺がん
• 大腸がん
• 前立腺がん
• 悪性黒色腫
• 白血病
• 卵巣がん
• 肝臓がん
• その他のがんの種類
• 世界のオンコロジーバイオマーカー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断
• 研究開発
• 予測
• リスクアセスメント
• その他の用途
• 世界のオンコロジーバイオマーカー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 学術およびがん調査機関
• 外来手術センター
• 診断検査室
• 世界のオンコロジーバイオマーカー市場、タンパク質バイオマーカーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍特異抗原
• 循環腫瘍細胞（CTC）
• 酵素バイオマーカー
• 世界のオンコロジーバイオマーカー市場、遺伝子バイオマーカーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• DNA変異
• 遺伝子発現プロファイル
• 一塩基多型（SNP）
• 世界のオンコロジーバイオマーカー市場、その他のがんバイオマーカーの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メタボロミクスバイオマーカー
• エピジェネティックバイオマーカー
• マイクロRNAバイオマーカー

第7章 地域別・国別分析

• 世界のオンコロジーバイオマーカー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のオンコロジーバイオマーカー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• オンコロジーバイオマーカー市場：競合情勢
• オンコロジーバイオマーカー市場：企業プロファイル
  • F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck KGaA
• Siemens Healthcare GmbH
• Becton Dickinson and Company
• GE Healthcare Technologies Inc.
• Eurofins Scientific SE
• Agilent Technologies Inc.
• Hologic Inc.
• Illumina Inc.
• Charles River Laboratories International Inc.
• bioMerieux SA
• Bio-Rad Laboratories Inc.
• Bruker Corporation
• QIAGEN NV
• Exact Sciences Corporation
• Sysmex Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• オンコロジーバイオマーカー市場2029：新たな機会を提供する国
• オンコロジーバイオマーカー市場2029：新たな機会を提供するセグメント
• オンコロジーバイオマーカー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Oncology biomarkers are biological indicators, such as genes, proteins, or other molecules, that can indicate the presence of cancer or its progression. They play a crucial role in diagnosing cancer, predicting treatment responses, and monitoring disease progression or recurrence. By analyzing these biomarkers, healthcare providers can create personalized treatment plans tailored to individual patients.

The primary categories of oncology biomarkers include protein biomarkers, genetic biomarkers, and others. Protein biomarkers involve the use of one or multiple proteins for diagnosing diseases, understanding prognosis, and monitoring a patient's biological response to treatment. Profiling technologies encompass omics technologies, imaging technologies, immunoassays, bioinformatics, and others. Cancer types covered by oncology biomarkers include breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, ovarian cancer, liver cancer, and others. These biomarkers find various applications such as diagnostics, research and development, prognostics, risk assessment, and more, predominantly utilized in hospitals, academic and cancer research institutes, ambulatory surgical centers, and diagnostic laboratories.

The oncology biomarkers market research report is one of a series of new reports from The Business Research Company that provides oncology biomarkers market statistics, including oncology biomarkers industry global market size, regional shares, competitors with a oncology biomarkers market share, detailed oncology biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biomarkers industry. This oncology biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncology biomarkers market size has grown rapidly in recent years. It will grow from $15.3 billion in 2024 to $17.43 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to adoption in emerging economies, precision medicine initiatives, diagnostic innovations, drug development support, increased cancer incidence

The oncology biomarkers market size is expected to see rapid growth in the next few years. It will grow to $29.64 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to integration of next-generation sequencing (ngs), expansion of biomarker informatics, focus on predictive pharmacogenomics, rapid development of exosome-based biomarkers, adoption of spatial transcriptomics. Major trends in the forecast period include standardization and quality assurance, shift towards functional biomarkers, role of biomarkers in clinical trials, expanded applications in immunotherapy, real-time monitoring of treatment responses.

The increasing incidence of cancer is expected to drive the growth of the oncology biomarker market in the coming years. Cancer is characterized by the uncontrolled growth of certain cells, which can then spread throughout the body. Oncological biomarkers provide valuable insights into the type of cancer by analyzing genes, proteins, and other substances in an individual's body. For example, in January 2024, the National Library of Medicine, a U.S. government institution, projected that there would be 2,001,140 new cancer cases and 611,720 cancer-related deaths in the United States in 2024. Additionally, incidence rates for cervical cancer among individuals aged 30 to 44 and colorectal cancer in those under 55 have been rising by 1% to 2% annually among young adults. Thus, the rising incidence of cancer is poised to significantly impact the oncology biomarker market.

The significant factor contributing to the growth of oncology biomarkers is the increasing adoption of personalized medicine. Personalized medicine is an innovative healthcare approach that tailors medical treatment to the individual characteristics of each patient. In the context of oncology biomarkers, personalized medicine utilizes specific biomarkers to identify unique genetic or molecular characteristics of an individual's cancer. As an illustration, in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% (12 of them) classified as personalized medicines by the Personalized Medicine Coalition (PMC). Hence, the growing adoption of personalized medicine serves as a driving force for the expansion of the oncology biomarker market.

The adoption of innovative and advanced technologies stands out as a prominent trend in the oncology biomarker market. Leading companies in this market are actively introducing new and groundbreaking technologies to enhance their position. In 2022, OncoDNA, a Belgium-based precision medicine company in oncology, launched OncoDEEP, a distinctive kit designed for laboratories to conduct comprehensive biomarker testing. OncoDEEP utilizes Next-generation sequencing (NGS) technology and cloud-based software tools, empowering laboratories to perform large-panel sequencing, acquire the molecular characterization of tumors, analyze raw data, and access robust quality controls.

Major players in the oncology biomarkers market are also focused on developing innovative products, such as clinical assays, to gain a competitive advantage. Clinical assays are biochemical tests used in healthcare to measure the presence or amount of a specific substance in biological samples such as blood, tissue, or urine. For instance, in December 2022, Adaptive Biotechnologies, a US-based biotechnology company, introduced the clonoSEQ Assay for detecting minimal residual disease (MRD) in blood for patients with diffuse large B-cell lymphoma (DLBCL). Leveraging circulating tumor DNA (ctDNA), clonoSEQ enables the assessment of MRD status in DLBCL, providing clinicians with a sensitive and quantitative measure of disease burden for earlier relapse detection and more precise treatment planning. Notably, it is the first and only MRD test in DLBCL with Medicare coverage across all lines of therapy, treatment regimens, and timepoints.

In May 2023, Freenome, a US-based biotech company, completed the acquisition of Oncimmune Ltd., a UK-based company specializing in developing immunodiagnostics. This strategic acquisition is poised to enhance Freenome's cancer screening efforts by providing additional clinical and commercial resources. Moreover, it will contribute to augmenting Freenome's multi-omics platform, offering a more comprehensive view of the tumor microenvironment.

Major companies operating in the oncology biomarkers market include F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Eli Lilly and Company, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Charles River Laboratories International Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Bristol -Myers Squibb Company, Agendia Inc., Epigenomics AG, OncoDNA SA

North America was the largest region in the oncology biomarkers market in 2024. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the oncology biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oncology biomarkers market consists of sales of epigenetic biomarkers, metabolic biomarkers and proteomic biomarkers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncology biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Biomarker Type: Protein Biomarkers; Genetic Biomarkers; Other Cancer Biomarkers
• 2) By Profiling Technologies: Omics Technologies; Imaging Technologies; Immunoassay; Bioinformatics; Other Profiling Technologies
• 3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Leukemia; Ovarian Cancer; Liver Cancer; Other Cancer Types
• 4) By Application: Diagnostics; Research And Development; Prognostics; Risk Assessment; Other Applications
• 5) By End-User: Hospitals; Academic And Cancer Research Institutes; Ambulatory Surgical Centers; Diagnostic Laboratories
• Subsegments:
• 1) By Protein Biomarkers: Tumor-Specific Antigens; Circulating Tumor Cells (CTCs); Enzymatic Biomarkers
• 2) By Genetic Biomarkers: DNA Mutations; Gene Expression Profiles; Single Nucleotide Polymorphisms (SNPs)
• 3) By Other Cancer Biomarkers: Metabolomic Biomarkers; Epigenetic Biomarkers; MicroRNA Biomarkers
• Companies Mentioned: F Hoffmann-La Roche AG; Novartis AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncology Biomarkers Market Characteristics

3. Oncology Biomarkers Market Trends And Strategies

4. Oncology Biomarkers Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Oncology Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oncology Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oncology Biomarkers Market Growth Rate Analysis
• 5.4. Global Oncology Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oncology Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oncology Biomarkers Total Addressable Market (TAM)

6. Oncology Biomarkers Market Segmentation

• 6.1. Global Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Protein Biomarkers
• Genetic Biomarkers
• Other Cancer Biomarkers
• 6.2. Global Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Omics Technologies
• Imaging Technologies
• Immunoassay
• Bioinformatics
• Other Profiling Technologies
• 6.3. Global Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Leukemia
• Ovarian Cancer
• Liver Cancer
• Other Cancer Types
• 6.4. Global Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostics
• Research And Development
• Prognostics
• Risk Assessment
• Other Applications
• 6.5. Global Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Academic And Cancer Research Institutes
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• 6.6. Global Oncology Biomarkers Market, Sub-Segmentation Of Protein Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor-Specific Antigens
• Circulating Tumor Cells (CTCs)
• Enzymatic Biomarkers
• 6.7. Global Oncology Biomarkers Market, Sub-Segmentation Of Genetic Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DNA Mutations
• Gene Expression Profiles
• Single Nucleotide Polymorphisms (SNPs)
• 6.8. Global Oncology Biomarkers Market, Sub-Segmentation Of Other Cancer Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metabolomic Biomarkers
• Epigenetic Biomarkers
• MicroRNA Biomarkers

7. Oncology Biomarkers Market Regional And Country Analysis

• 7.1. Global Oncology Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oncology Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncology Biomarkers Market

• 8.1. Asia-Pacific Oncology Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncology Biomarkers Market

• 9.1. China Oncology Biomarkers Market Overview
• 9.2. China Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncology Biomarkers Market

• 10.1. India Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncology Biomarkers Market

• 11.1. Japan Oncology Biomarkers Market Overview
• 11.2. Japan Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncology Biomarkers Market

• 12.1. Australia Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncology Biomarkers Market

• 13.1. Indonesia Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncology Biomarkers Market

• 14.1. South Korea Oncology Biomarkers Market Overview
• 14.2. South Korea Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncology Biomarkers Market

• 15.1. Western Europe Oncology Biomarkers Market Overview
• 15.2. Western Europe Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncology Biomarkers Market

• 16.1. UK Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncology Biomarkers Market

• 17.1. Germany Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncology Biomarkers Market

• 18.1. France Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncology Biomarkers Market

• 19.1. Italy Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncology Biomarkers Market

• 20.1. Spain Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncology Biomarkers Market

• 21.1. Eastern Europe Oncology Biomarkers Market Overview
• 21.2. Eastern Europe Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncology Biomarkers Market

• 22.1. Russia Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncology Biomarkers Market

• 23.1. North America Oncology Biomarkers Market Overview
• 23.2. North America Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncology Biomarkers Market

• 24.1. USA Oncology Biomarkers Market Overview
• 24.2. USA Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncology Biomarkers Market

• 25.1. Canada Oncology Biomarkers Market Overview
• 25.2. Canada Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncology Biomarkers Market

• 26.1. South America Oncology Biomarkers Market Overview
• 26.2. South America Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncology Biomarkers Market

• 27.1. Brazil Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncology Biomarkers Market

• 28.1. Middle East Oncology Biomarkers Market Overview
• 28.2. Middle East Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncology Biomarkers Market

• 29.1. Africa Oncology Biomarkers Market Overview
• 29.2. Africa Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncology Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Oncology Biomarkers Market Competitive Landscape
• 30.2. Oncology Biomarkers Market Company Profiles
  • 30.2.1. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Oncology Biomarkers Market Other Major And Innovative Companies

• 31.1. Merck KGaA
• 31.2. Siemens Healthcare GmbH
• 31.3. Becton Dickinson and Company
• 31.4. GE Healthcare Technologies Inc.
• 31.5. Eurofins Scientific SE
• 31.6. Agilent Technologies Inc.
• 31.7. Hologic Inc.
• 31.8. Illumina Inc.
• 31.9. Charles River Laboratories International Inc.
• 31.10. bioMerieux SA
• 31.11. Bio-Rad Laboratories Inc.
• 31.12. Bruker Corporation
• 31.13. QIAGEN NV
• 31.14. Exact Sciences Corporation
• 31.15. Sysmex Corporation

32. Global Oncology Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncology Biomarkers Market

34. Recent Developments In The Oncology Biomarkers Market

35. Oncology Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Oncology Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oncology Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oncology Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer